By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Oculus Innovative Sciences, Inc. 

1135 North McDowell Boulevard

Petaluma  California  94954  U.S.A.
Phone: 707-782-0792 Fax: 707-782-0705


SEARCH JOBS

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures, and markets a family of Microcyn® Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus’ platform technology, called Microcyn, is a non-irritating proprietary oxychlorine formulation designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V.

Last Updated: 05-23-2007

Key Statistics


Email: hr@oculusis.com
Ownership: Public

Web Site: Oculus Innovative Sciences, Inc.
Employees:
Symbol: OCLS
 









Company News
Oculus Innovative Sciences, Inc. (OCLS) Strengthens Intellectual Property Portfolio With Allowance Of Four New Patents For Microcyn® Technology 9/16/2014 1:14:03 PM
Oculus Innovative Sciences, Inc. (OCLS) Introduces Microcyn®-Based Over-The-Counter Advanced Scar Management Hydrogel In United States 9/10/2014 8:26:44 AM
Oculus Innovative Sciences, Inc. (OCLS) Reports Revenues Of $3.4 Million And Net Loss Of $70,000 For First Quarter Of Fiscal 2015 8/8/2014 8:50:21 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal First Quarter 2015 Financial Results And Conference Call 7/24/2014 10:35:52 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal Fourth Quarter 2014 Financial Results And Conference Call 7/9/2014 9:14:50 AM
Oculus Innovative Sciences, Inc. (OCLS) Reports Revenues Of $2.9 Million And Net Income Of $7.5 Million For Fourth Quarter Of Fiscal 2014 Primarily Due To Accounting Treatment Of Ruthigen IPO Transaction 6/13/2014 8:08:01 AM
Oculus Innovative Sciences, Inc. (OCLS) Sciences Announces Fiscal Fourth Quarter 2014 Financial Results And Conference Call 5/29/2014 8:54:07 AM
Oculus Innovative Sciences, Inc. (OCLS)' Partner, More Pharma Corporation, Launches Microcyn®-Based Oral And Throat Infection Treatment Product In Mexico 4/22/2014 8:54:54 AM
Oculus Innovative Sciences, Inc. (OCLS) Receives "Strong Consensus" Rating For Use With Kinetic Concepts, Inc. (KCI)' Negative Pressure Wound Therapy With Instillation 4/9/2014 8:00:55 AM
Oculus Innovative Sciences, Inc. (OCLS) Shakes Up Board Following Ruthigen IPO 4/2/2014 9:23:36 AM
12345678910...
//-->